Literature DB >> 69168

Epipodophylin derivative (VP 16-23) in malignant teratomas and choriocarcinomas.

E S Newlands, K D Bagshawe.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 69168     DOI： 10.1016/s0140-6736(77)90088-5

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  9 in total

1.  Chemotherapy for non-seminomatous germ-cell tumours.

Authors:  P M Wilkinson
Journal:  J R Soc Med       Date:  1985       Impact factor: 5.344

Review 2.  Oral etoposide in germ cell tumours.

Authors:  S Saxman
Journal:  Drugs       Date:  1999       Impact factor: 9.546

Review 3.  Teniposide: overview of its therapeutic potential in adult cancers.

Authors:  F M Muggia
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 4.  Etoposide: current status and future perspectives in the management of malignant neoplasms.

Authors:  C P Belani; L A Doyle; J Aisner
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

5.  Pharmacokinetics and toxicity of the epipodophyllotoxin derivative etoposide (VP 16-213) in patients with gestational choriocarcinoma and malignant teratoma.

Authors:  C J Brindley; P Antoniw; E S Newlands; K D Bagshawe
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

6.  [Etoposide VP 16--213)--a podophyllotoxinderivative with high antitumor activity (author's transl)].

Authors:  H J Schmoll; N Niederle; W Achterrath
Journal:  Klin Wochenschr       Date:  1981-11-02

Review 7.  The role of surgery in metastatic testicular germ cell tumours (GCT).

Authors:  E S Newlands; K W Reynolds
Journal:  Br J Cancer       Date:  1989-06       Impact factor: 7.640

8.  Chemotherapy of advanced malignant teratomas.

Authors:  E S Newlands; R H Begent; S B Kaye; G J Rustin; K D Bagshawe
Journal:  Br J Cancer       Date:  1980-09       Impact factor: 7.640

9.  The treatment of metastatic germ-cell testicular tumours with bleomycin, etoposide and cis-platin (BEP).

Authors:  M J Peckham; A Barrett; K H Liew; A Horwich; B Robinson; H J Dobbs; T J McElwain; W F Hendry
Journal:  Br J Cancer       Date:  1983-05       Impact factor: 7.640
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.